51
|
Benjamin SR, Jackson CP, Fang S, Carlson DP, Guo Z, Tumey LN. Thiolation of Q295: Site-Specific Conjugation of Hydrophobic Payloads without the Need for Genetic Engineering. Mol Pharm 2019; 16:2795-2807. [PMID: 31067063 DOI: 10.1021/acs.molpharmaceut.9b00323] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Site-specific conjugation technology frequently relies on antibody engineering to incorporate rare or non-natural amino acids into the primary sequence of the protein. However, when the primary sequence is unknown or when antibody engineering is not feasible, there are very limited options for site-specific protein modification. We have developed a transglutaminase-mediated conjugation that incorporates a thiol at a "privileged" location on deglycosylated antibodies (Q295). Perhaps surprisingly, this conjugation employs a reported transglutaminase inhibitor, cystamine, as the key enzyme substrate. The chemical incorporation of a thiol at the Q295 site allows for the site-specific attachment of a plethora of commonly used and commercially available payloads via maleimide chemistry. Herein, we demonstrate the utility of this method by comparing the conjugatability, plasma stability, and in vitro potency of these site-specific antibody-drug conjugates (ADCs) with analogous endogenous cysteine conjugates. Cytotoxic ADCs prepared using this methodology are shown to exhibit comparable in vitro efficacy to stochastic cysteine conjugates while displaying dramatically improved plasma stability and conjugatability. In particular, we note that this technique appears to be useful for the incorporation of highly hydrophobic linker payloads without the addition of PEG modifiers. We postulate a possible mechanism for this feature by probing the local environment of the Q295 site with two fluorescent probes that are known to be sensitive to the local hydrophobic environment. In summary, we describe a highly practical method for the site-specific conjugation of genetically nonengineered antibodies, which results in plasma-stable ADCs with low intrinsic hydrophobicity. We believe that this technology will find broad utility in the ADC community.
Collapse
Affiliation(s)
- Samantha R Benjamin
- School of Pharmacy and Pharmaceutical Sciences , Binghamton University , P.O. Box 6000, Binghamton , New York 13902 , United States
| | - Courtney P Jackson
- School of Pharmacy and Pharmaceutical Sciences , Binghamton University , P.O. Box 6000, Binghamton , New York 13902 , United States
| | - Siteng Fang
- School of Pharmacy and Pharmaceutical Sciences , Binghamton University , P.O. Box 6000, Binghamton , New York 13902 , United States
| | - Dane P Carlson
- School of Pharmacy and Pharmaceutical Sciences , Binghamton University , P.O. Box 6000, Binghamton , New York 13902 , United States
| | - Zhongyuan Guo
- School of Pharmacy and Pharmaceutical Sciences , Binghamton University , P.O. Box 6000, Binghamton , New York 13902 , United States
| | - L Nathan Tumey
- School of Pharmacy and Pharmaceutical Sciences , Binghamton University , P.O. Box 6000, Binghamton , New York 13902 , United States
| |
Collapse
|
52
|
Sengee M, Eksteen JJ, Nergård SL, Vasskog T, Sydnes LK. Preparation and Assessment of Self-Immolative Linkers for Therapeutic Bioconjugates with Amino- and Hydroxyl-Containing Cargoes. Bioconjug Chem 2019; 30:1489-1499. [DOI: 10.1021/acs.bioconjchem.9b00214] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Myagmarsuren Sengee
- NORCE Norwegian Research Centre AS, P.O. Box
6434, Tromsø Science Park, NO-9294 Tromsø, Norway
| | - J. Johannes Eksteen
- NORCE Norwegian Research Centre AS, P.O. Box
6434, Tromsø Science Park, NO-9294 Tromsø, Norway
| | - Silje Lillemark Nergård
- Department of Pharmacy, UiT The Arctic University of Norway, P.O. Box 6050, Langnes, NO-9037 Tromsø, Norway
| | - Terje Vasskog
- NORCE Norwegian Research Centre AS, P.O. Box
6434, Tromsø Science Park, NO-9294 Tromsø, Norway
- Department of Pharmacy, UiT The Arctic University of Norway, P.O. Box 6050, Langnes, NO-9037 Tromsø, Norway
| | - Leiv K. Sydnes
- NORCE Norwegian Research Centre AS, P.O. Box
6434, Tromsø Science Park, NO-9294 Tromsø, Norway
- Department of Chemistry, University of Bergen, P.O. Box 7800, NO-5020 Bergen, Norway
| |
Collapse
|
53
|
Method development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker drug analyte. Anal Bioanal Chem 2019; 411:2587-2596. [DOI: 10.1007/s00216-019-01701-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2018] [Revised: 02/11/2019] [Accepted: 02/18/2019] [Indexed: 01/24/2023]
|
54
|
Costa MJ, Kudaravalli J, Ma JT, Ho WH, Delaria K, Holz C, Stauffer A, Chunyk AG, Zong Q, Blasi E, Buetow B, Tran TT, Lindquist K, Dorywalska M, Rajpal A, Shelton DL, Strop P, Liu SH. Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates. Sci Rep 2019; 9:2443. [PMID: 30792442 PMCID: PMC6384886 DOI: 10.1038/s41598-019-38745-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Accepted: 01/09/2019] [Indexed: 12/15/2022] Open
Abstract
Antibody-drug conjugates (ADCs) are promising therapies for haematological cancers. Historically, their therapeutic benefit is due to ADC targeting of lineage-restricted antigens. The C-X-C motif chemokine receptor 4 (CXCR4) is attractive for targeted therapy of haematological cancers, given its expression in multiple tumour types and role in cancer "homing" to bone marrow. However, CXCR4 is also expressed in haematopoietic cells and other normal tissues, raising safety challenges to the development of anti-CXCR4 ADCs for cancer treatment. Here, we designed the first anti-CXCR4 ADC with favourable therapeutic index, effective in xenografts of haematopoietic cancers resistant to standard of care and anti-CXCR4 antibodies. We screened multiple ADC configurations, by varying type of linker-payload, drug-to-antibody ratio (DAR), affinity and Fc format. The optimal ADC bears a non-cleavable linker, auristatin as payload at DAR = 4 and a low affinity antibody with effector-reduced Fc. Contrary to other drugs targeting CXCR4, anti-CXCR4 ADCs effectively eliminated cancer cells as monotherapy, while minimizing leucocytosis. The optimal ADC selectively eliminated CXCR4+ cancer cells in solid tumours, but showed limited toxicity to normal CXCR4+ tissues, sparing haematopoietic stem cells and progenitors. Our work provides proof-of-concept that through empirical ADC design, it is possible to target proteins with broad normal tissue expression.
Collapse
Affiliation(s)
- Maria José Costa
- Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA.
| | - Jyothirmayee Kudaravalli
- Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA
| | - Jing-Tyan Ma
- Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA
| | - Wei-Hsien Ho
- Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA.,Alector, 151, Oyster Point Blvd, suite 300, South San Francisco, CA, 94080, USA
| | - Kathy Delaria
- Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA.,Grifols Diagnostic Solutions, 6455 Christie Ave B-334C, Emeryville, CA, 94608, USA
| | - Charles Holz
- Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA.,Grifols Diagnostic Solutions, 6455 Christie Ave B-334C, Emeryville, CA, 94608, USA
| | - Angela Stauffer
- BioMedicine Design, Medicinal Sciences, Worldwide Research and Development, Pfizer Inc., 10646 Science Center Dr, San Diego, CA, 92121, USA
| | - Allison Given Chunyk
- BioMedicine Design, Medicinal Sciences, Worldwide Research and Development, Pfizer Inc., 10646 Science Center Dr, San Diego, CA, 92121, USA
| | - Qing Zong
- Drug Safety Research and Development, Worldwide Research and Development, Pfizer Inc., 10646 Science Center Dr, San Diego, CA, 92121, USA
| | - Eileen Blasi
- Drug Safety Research and Development, Worldwide Research and Development, Pfizer Inc., 10646 Science Center Dr, San Diego, CA, 92121, USA
| | - Bernard Buetow
- Drug Safety Research and Development, Worldwide Research and Development, Pfizer Inc., 10646 Science Center Dr, San Diego, CA, 92121, USA
| | - Thomas-Toan Tran
- Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA.,NGM Biopharmaceuticals, Inc, 630 Gateway Blvd, South San Francisco, CA, 94080, USA
| | - Kevin Lindquist
- Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA
| | - Magdalena Dorywalska
- Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA
| | - Arvind Rajpal
- Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA.,Bristol-Myers Squibb, 700 Bay Rd suite A, Redwood City, CA, 94063, USA
| | - David L Shelton
- Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA
| | - Pavel Strop
- Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA.,Bristol-Myers Squibb, 700 Bay Rd suite A, Redwood City, CA, 94063, USA
| | - Shu-Hui Liu
- Cancer Immunology Discovery, Oncology Research and Development, Worldwide Research and Development, Pfizer Inc., 230 E Grand Ave, South San Francisco, CA, 94080, USA.,Multitude Therapeutics, Abmart, Redwood City, CA, 94063, USA
| |
Collapse
|
55
|
Characterization of Ring-Opening Reaction of Succinimide Linkers in ADCs. J Pharm Sci 2019; 108:133-141. [DOI: 10.1016/j.xphs.2018.10.063] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2018] [Revised: 09/17/2018] [Accepted: 10/30/2018] [Indexed: 11/18/2022]
|
56
|
Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. Cleavable linkers in antibody–drug conjugates. Chem Soc Rev 2019; 48:4361-4374. [DOI: 10.1039/c8cs00676h] [Citation(s) in RCA: 188] [Impact Index Per Article: 37.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
This tutorial review summarises the advances in the field of cleavable linker technologies for antibody–drug conjugates (ADCs).
Collapse
Affiliation(s)
| | | | - Jeremy S. Parker
- Early Chemical Development
- Pharmaceutical Sciences
- IMED Biotech Unit
- AstraZeneca
- Macclesfield
| | - David R. Spring
- Department of Chemistry
- University of Cambridge
- Cambridge CB2 1EW
- UK
| |
Collapse
|
57
|
Dickgiesser S, Deweid L, Kellner R, Kolmar H, Rasche N. Site-Specific Antibody-Drug Conjugation Using Microbial Transglutaminase. Methods Mol Biol 2019; 2012:135-149. [PMID: 31161507 DOI: 10.1007/978-1-4939-9546-2_8] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Antibody-drug conjugates (ADCs) are a relatively young class of cancer therapeutics that combine the superior selectivity of monoclonal antibodies (mAbs) with the high potency of cytotoxic agents. In the first generation of ADCs, the toxic payload is attached to the mAb via chemical conjugation to endogenous lysine or cysteine residues providing only limited control over site specificity and drug-to-antibody ratio (DAR). The resulting product is a heterogeneous population of different ADC species, each with individual characteristics concerning pharmacokinetics, toxicology, and efficacy. Such diverse ADC mixtures are not only difficult to develop but are potentially also accompanied by a suboptimal therapeutic window. To overcome these limitations, alternative conjugation technologies have been developed that allow the production of tailor-made homogeneous ADCs. Due to its high specificity and robust applicability, microbial transglutaminase (mTG), a protein-glutamine γ-glutamyltransferase isolated from Streptomyces mobaraensis, emerged as a versatile tool for ADC manufacturing. Herein, we report a protocol for the site-specific, mTG-mediated modification of antibodies that allows the production of homogeneous and defined ADCs. Moreover, analytical methods for ADC characterization are provided.
Collapse
Affiliation(s)
| | - Lukas Deweid
- Clemens-Schöpf Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Darmstadt, Germany
| | - Roland Kellner
- ADCs & Targeted NBE Therapeutics, Merck KGaA, Darmstadt, Germany
| | - Harald Kolmar
- Clemens-Schöpf Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Darmstadt, Germany
| | - Nicolas Rasche
- ADCs & Targeted NBE Therapeutics, Merck KGaA, Darmstadt, Germany
| |
Collapse
|
58
|
ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates. Antibodies (Basel) 2018; 7:antib7040041. [PMID: 31544891 PMCID: PMC6698957 DOI: 10.3390/antib7040041] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Revised: 11/21/2018] [Accepted: 11/26/2018] [Indexed: 12/19/2022] Open
Abstract
Antibody-drug conjugates (ADCs) are a unique class of biotherapeutics of inherent heterogeneity and correspondingly complex absorption, distribution, metabolism, and excretion (ADME) properties. Herein, we consider the contribution of various components of ADCs such as various classes of warheads, linkers, and conjugation strategies on ADME of ADCs. Understanding the metabolism and disposition of ADCs and interpreting exposure-efficacy and exposure-safety relationships of ADCs in the context of their various catabolites is critical for design and subsequent development of a clinically successful ADCs. Sophisticated bioanalytical assays are required for the assessments of intact ADC, total antibody, released warhead and relevant metabolites. Both ligand-binding assays (LBA) and hybrid LBA-liquid chromatography coupled with tandem mass spectrometry (LBA-LC-MS/MS) methods have been employed to assess pharmacokinetics (PK) of ADCs. Future advances in bioanalytical techniques will need to address the rising complexity of this biotherapeutic modality as more innovative conjugation strategies, antibody scaffolds and novel classes of warheads are employed for the next generation of ADCs. This review reflects our considerations on ADME of ADCs and provides a perspective on the current bioanalytical strategies for pharmacokinetic assessments of ADCs.
Collapse
|
59
|
Liu-Shin LPY, Fung A, Malhotra A, Ratnaswamy G. Evidence of disulfide bond scrambling during production of an antibody-drug conjugate. MAbs 2018; 10:1190-1199. [PMID: 30339473 DOI: 10.1080/19420862.2018.1521128] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Antibody-drug conjugates (ADCs) that are formed using thiol-maleimide chemistry are commonly produced by reactions that occur at or above neutral pHs. Alkaline environments can promote disulfide bond scrambling, and may result in the reconfiguration of interchain disulfide bonds in IgG antibodies, particularly in the IgG2 and IgG4 subclasses. IgG2-A and IgG2-B antibodies generated under basic conditions yielded ADCs with comparable average drug-to-antibody ratios and conjugate distributions. In contrast, the antibody disulfide configuration affected the distribution of ADCs generated under acidic conditions. The similarities of the ADCs derived from alkaline reactions were attributed to the scrambling of interchain disulfide bonds during the partial reduction step, where conversion of the IgG2-A isoform to the IgG2-B isoform was favored.
Collapse
Affiliation(s)
- Lily Pei-Yao Liu-Shin
- a Analytical and Formulation Development , Agensys, Inc., an affiliate of Astellas, Inc , Santa Monica , CA , USA.,b Department of Biochemistry and Molecular Biology , University of Miami Miller School of Medicine , Miami , FL , USA
| | - Adam Fung
- a Analytical and Formulation Development , Agensys, Inc., an affiliate of Astellas, Inc , Santa Monica , CA , USA
| | - Arun Malhotra
- b Department of Biochemistry and Molecular Biology , University of Miami Miller School of Medicine , Miami , FL , USA
| | - Gayathri Ratnaswamy
- a Analytical and Formulation Development , Agensys, Inc., an affiliate of Astellas, Inc , Santa Monica , CA , USA
| |
Collapse
|
60
|
Huang BCB, Kim YC, Bañas S, Barfield RM, Drake PM, Rupniewski I, Haskins WE, Rabuka D. Antibody-drug conjugate library prepared by scanning insertion of the aldehyde tag into IgG1 constant regions. MAbs 2018; 10:1182-1189. [PMID: 30252630 PMCID: PMC6284588 DOI: 10.1080/19420862.2018.1512327] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The advantages of site-specific over stochastic bioconjugation technologies include homogeneity of product, minimal perturbation of protein structure/function, and – increasingly – the ability to perform structure activity relationship studies at the conjugate level. When selecting the optimal location for site-specific payload placement, many researchers turn to in silico modeling of protein structure to identify regions predicted to offer solvent-exposed conjugatable sites while conserving protein function. Here, using the aldehyde tag as our site-specific technology platform and human IgG1 antibody as our target protein, we demonstrate the power of taking an unbiased scanning approach instead. Scanning insertion of the human formylglycine generating enzyme (FGE) recognition sequence, LCTPSR, at each of the 436 positions in the light and heavy chain antibody constant regions followed by co-expression with FGE yielded a library of antibodies bearing an aldehyde functional group ready for conjugation. Each of the variants was expressed, purified, and conjugated to a cytotoxic payload using the Hydrazinyl Iso-Pictet-Spengler ligation to generate an antibody-drug conjugate (ADC), which was analyzed in terms of conjugatability (assessed by drug-to-antibody ratio, DAR) and percent aggregate. We searched for insertion sites that could generate manufacturable ADCs, defined as those variants yielding reasonable antibody titers, DARs of ≥ 1.3, and ≥ 95% monomeric species. Through this process, we discovered 58 tag insertion sites that met these metrics, including 14 sites in the light chain, a location that had proved refractory to the placement of manufacturable tag sites using in silico modeling/rational approaches.
Collapse
|
61
|
Datta-Mannan A, Choi H, Stokell D, Tang J, Murphy A, Wrobleski A, Feng Y. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass. AAPS JOURNAL 2018; 20:103. [DOI: 10.1208/s12248-018-0263-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Accepted: 09/06/2018] [Indexed: 01/11/2023]
|
62
|
Wong OK, Tran TT, Ho WH, Casas MG, Au M, Bateman M, Lindquist KC, Rajpal A, Shelton DL, Strop P, Liu SH. RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models. Oncotarget 2018; 9:33446-33458. [PMID: 30323890 PMCID: PMC6173368 DOI: 10.18632/oncotarget.26002] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Accepted: 08/06/2018] [Indexed: 12/15/2022] Open
Abstract
Epidermal growth factor receptor (EGFR) is a clinically validated target and often overexpressed in some solid tumors. Both EGFR tyrosine kinase inhibitors and ligand-blocking antibodies have been approved for treatment of NSCLC, head and neck cancers and colorectal cancers. However, clinical response is limited and often accompanied by significant toxicities due to normal tissue expression. To improve the effectiveness of targeting EGFR while minimizing the toxicities on normal tissues, we developed a low-affinity anti-EGFR antibody drug conjugate (ADC), RN765C. Potent in vitro cytotoxicity of RN765C, with nanomolar to subnanomolar EC50, was observed on a panel of cancer cell lines expressing moderate to high level of EGFR. In contrast, RN765C was less effective in killing normal human keratinocytes, presumably due to its lower receptor expression. Mechanistically, RN765C has multiple modes of action: inducing payload mediated mitotic arrest and cell death, blocking EGFR pathway signal and mediating antibody dependent cell cytotoxicity. In preclinical studies, a single dose of RN765C at 1.5-3 mg/kg was generally sufficient to induce tumor regression in multiple cell line and patient-derived xenograft models, including those that are resistant to EGFR-directed tyrosine kinase inhibitors. Our data support further investigation of RN765C in the clinic to treat EGFR expressing solid tumors.
Collapse
Affiliation(s)
- Oi Kwan Wong
- Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.,Allogene Therapeutics, South San Francisco, CA, USA
| | - Thomas-Toan Tran
- Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.,NGM Biopharmaceuticals, South San Francisco, CA, USA
| | - Wei-Hsien Ho
- Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.,Alector Inc., South San Francisco, CA, USA
| | - Meritxell Galindo Casas
- Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.,acib GmbH Graz, Graz, Austria
| | - Melinda Au
- Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.,Allogene Therapeutics, South San Francisco, CA, USA
| | - Marjorie Bateman
- Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA
| | - Kevin C Lindquist
- Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA
| | - Arvind Rajpal
- Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.,Bristol-Myers Squibb, Redwood City, CA, USA
| | - David L Shelton
- Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA
| | - Pavel Strop
- Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.,Bristol-Myers Squibb, Redwood City, CA, USA
| | - Shu-Hui Liu
- Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.,Abmart Inc., Redwood City, CA, USA
| |
Collapse
|
63
|
Anami Y, Yamazaki CM, Xiong W, Gui X, Zhang N, An Z, Tsuchikama K. Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice. Nat Commun 2018; 9:2512. [PMID: 29955061 PMCID: PMC6023893 DOI: 10.1038/s41467-018-04982-3] [Citation(s) in RCA: 105] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Accepted: 06/05/2018] [Indexed: 11/24/2022] Open
Abstract
Valine-citrulline linkers are commonly used as enzymatically cleavable linkers for antibody-drug conjugates. While stable in human plasma, these linkers are unstable in mouse plasma due to susceptibility to an extracellular carboxylesterase. This instability often triggers premature release of drugs in mouse circulation, presenting a molecular design challenge. Here, we report that an antibody-drug conjugate with glutamic acid-valine-citrulline linkers is responsive to enzymatic drug release but undergoes almost no premature cleavage in mice. We demonstrate that this construct exhibits greater treatment efficacy in mouse tumor models than does a valine-citrulline-based variant. Notably, our antibody-drug conjugate contains long spacers facilitating the protease access to the linker moiety, indicating that our linker assures high in vivo stability despite a high degree of exposure. This technology could add flexibility to antibody-drug conjugate design and help minimize failure rates in pre-clinical studies caused by linker instability.
Collapse
Affiliation(s)
- Yasuaki Anami
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA
| | - Chisato M Yamazaki
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA
| | - Wei Xiong
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA
| | - Xun Gui
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA
| | - Ningyan Zhang
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA
| | - Zhiqiang An
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA
| | - Kyoji Tsuchikama
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA.
| |
Collapse
|
64
|
Tsumura R, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. J Control Release 2018; 284:49-56. [PMID: 29906553 DOI: 10.1016/j.jconrel.2018.06.016] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 06/07/2018] [Accepted: 06/11/2018] [Indexed: 10/14/2022]
Abstract
Antibody-drug conjugates (ADCs) are currently considered to be promising agents for cancer therapy. However, especially in solid tumors, the uneven distribution of ADCs would decrease their efficacy in clinical studies. We suggest that in addition to optimizing ADC components, such as the linker structure and anticancer agent, it is necessary to consider the distribution of the ADC within tumor tissue. In this study, we established three kinds of anti-tissue factor (TF) ADCs: 1849ADC with a low kd, 444ADC with an intermediate kd, and 1084ADC with a high kd. All three of the anti-TF ADCs exhibited almost the same in vitro cytotoxicity and pharmacological and biochemical characteristics, although the binding kinetics parameters differed. In vivo, all ADCs exerted equivalent antitumor effects against small BxPC3 tumors. However, on larger BxPC3 tumors, 1084ADC (higher kd) exerted higher antitumor activity than 1849ADC (lower kd). Furthermore, immunofluorescence staining indicated that 1084ADC was distributed throughout the whole tumor, whereas 1849ADC was mainly localized close to tumor vessels. We conclude that the ADC with a higher kd increased the antitumor effect of because it penetrated and distributed evenly throughout the entire solid tumor. These findings highlight the importance of the kd of a mAb in ADC design.
Collapse
Affiliation(s)
- Ryo Tsumura
- Division of Developmental Therapeutics, EPOC, National Cancer Center, Kashiwa, Japan.
| | - Shino Manabe
- Synthetic Cellular Chemistry Laboratory, RIKEN, Wako, Japan.
| | - Hiroki Takashima
- Division of Developmental Therapeutics, EPOC, National Cancer Center, Kashiwa, Japan.
| | - Yoshikatsu Koga
- Division of Developmental Therapeutics, EPOC, National Cancer Center, Kashiwa, Japan.
| | - Masahiro Yasunaga
- Division of Developmental Therapeutics, EPOC, National Cancer Center, Kashiwa, Japan.
| | - Yasuhiro Matsumura
- Division of Developmental Therapeutics, EPOC, National Cancer Center, Kashiwa, Japan.
| |
Collapse
|
65
|
Ohri R, Bhakta S, Fourie-O'Donohue A, Dela Cruz-Chuh J, Tsai SP, Cook R, Wei B, Ng C, Wong AW, Bos AB, Farahi F, Bhakta J, Pillow TH, Raab H, Vandlen R, Polakis P, Liu Y, Erickson H, Junutula JR, Kozak KR. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers. Bioconjug Chem 2018; 29:473-485. [PMID: 29425028 DOI: 10.1021/acs.bioconjchem.7b00791] [Citation(s) in RCA: 70] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
THIOMAB antibody technology utilizes cysteine residues engineered onto an antibody to allow for site-specific conjugation. The technology has enabled the exploration of different attachment sites on the antibody in combination with small molecules, peptides, or proteins to yield antibody conjugates with unique properties. As reported previously ( Shen , B. Q. , et al. ( 2012 ) Nat. Biotechnol. 30 , 184 - 189 ; Pillow , T. H. , et al. ( 2017 ) Chem. Sci. 8 , 366 - 370 ), the specific location of the site of conjugation on an antibody can impact the stability of the linkage to the engineered cysteine for both thio-succinimide and disulfide bonds. High stability of the linkage is usually desired to maximize the delivery of the cargo to the intended target. In the current study, cysteines were individually substituted into every position of the anti-HER2 antibody (trastuzumab), and the stabilities of drug conjugations at those sites were evaluated. We screened a total of 648 THIOMAB antibody-drug conjugates, each generated from a trastuzamab prepared by sequentially mutating non-cysteine amino acids in the light and heavy chains to cysteine. Each THIOMAB antibody variant was conjugated to either maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethyl auristatin E (MC-vc-PAB-MMAE) or pyridyl disulfide monomethyl auristatin E (PDS-MMAE) using a high-throughput, on-bead conjugation and purification method. Greater than 50% of the THIOMAB antibody variants were successfully conjugated to both MMAE derivatives with a drug to antibody ratio (DAR) of >0.5 and <50% aggregation. The relative in vitro plasma stabilities for approximately 750 conjugates were assessed using enzyme-linked immunosorbent assays, and stable sites were confirmed with affinity-capture LC/MS-based detection methods. Highly stable conjugation sites for the two types of MMAE derivatives were identified on both the heavy and light chains. Although the stabilities of maleimide conjugates were shown to be greater than those of the disulfide conjugates, many sites were identified that were stable for both. Furthermore, in vitro stabilities of selected stable sites translated across different cytotoxic payloads and different target antibodies as well as to in vivo stability.
Collapse
Affiliation(s)
- Rachana Ohri
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Sunil Bhakta
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | | | | | - Siao Ping Tsai
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Ryan Cook
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Binqing Wei
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Carl Ng
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Athena W Wong
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Aaron B Bos
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Farzam Farahi
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Jiten Bhakta
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Thomas H Pillow
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Helga Raab
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Richard Vandlen
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Paul Polakis
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Yichin Liu
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Hans Erickson
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Jagath R Junutula
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Katherine R Kozak
- Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
66
|
Enzyme-Based Labeling Strategies for Antibody-Drug Conjugates and Antibody Mimetics. Antibodies (Basel) 2018; 7:antib7010004. [PMID: 31544857 PMCID: PMC6698867 DOI: 10.3390/antib7010004] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2017] [Revised: 12/15/2017] [Accepted: 12/18/2017] [Indexed: 01/25/2023] Open
Abstract
Strategies for site-specific modification of proteins have increased in number, complexity, and specificity over the last years. Such modifications hold the promise to broaden the use of existing biopharmaceuticals or to tailor novel proteins for therapeutic or diagnostic applications. The recent quest for next-generation antibody–drug conjugates (ADCs) sparked research into techniques with site selectivity. While purely chemical approaches often impede control of dosage or locus of derivatization, naturally occurring enzymes and proteins bear the ability of co- or post-translational protein modifications at particular residues, thus enabling unique coupling reactions or protein fusions. This review provides a general overview and focuses on chemo-enzymatic methods including enzymes such as formylglycine-generating enzyme, sortase, and transglutaminase. Applications for the conjugation of antibodies and antibody mimetics are reported.
Collapse
|
67
|
Wei B, Gunzner-Toste J, Yao H, Wang T, Wang J, Xu Z, Chen J, Wai J, Nonomiya J, Tsai SP, Chuh J, Kozak KR, Liu Y, Yu SF, Lau J, Li G, Phillips GD, Leipold D, Kamath A, Su D, Xu K, Eigenbrot C, Steinbacher S, Ohri R, Raab H, Staben LR, Zhao G, Flygare JA, Pillow TH, Verma V, Masterson LA, Howard PW, Safina B. Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity. J Med Chem 2017; 61:989-1000. [PMID: 29227683 DOI: 10.1021/acs.jmedchem.7b01430] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Antibody-drug conjugates (ADCs) have become an important therapeutic modality for oncology, with three approved by the FDA and over 60 others in clinical trials. Despite the progress, improvements in ADC therapeutic index are desired. Peptide-based ADC linkers that are cleaved by lysosomal proteases have shown sufficient stability in serum and effective payload-release in targeted cells. If the linker can be preferentially hydrolyzed by tumor-specific proteases, safety margin may improve. However, the use of peptide-based linkers limits our ability to modulate protease specificity. Here we report the structure-guided discovery of novel, nonpeptidic ADC linkers. We show that a cyclobutane-1,1-dicarboxamide-containing linker is hydrolyzed predominantly by cathepsin B while the valine-citrulline dipeptide linker is not. ADCs bearing the nonpeptidic linker are as efficacious and stable in vivo as those with the dipeptide linker. Our results strongly support the application of the peptidomimetic linker and present new opportunities for improving the selectivity of ADCs.
Collapse
Affiliation(s)
- BinQing Wei
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Janet Gunzner-Toste
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Hui Yao
- WuXi AppTec , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Tao Wang
- WuXi AppTec , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Jing Wang
- WuXi AppTec , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Zijin Xu
- WuXi AppTec , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Jinhua Chen
- WuXi AppTec , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - John Wai
- WuXi AppTec , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Jim Nonomiya
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Siao Ping Tsai
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Josefa Chuh
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Katherine R Kozak
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Yichin Liu
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Shang-Fan Yu
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Jeff Lau
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Guangmin Li
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Gail D Phillips
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Doug Leipold
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Amrita Kamath
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Dian Su
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Keyang Xu
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Charles Eigenbrot
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Stefan Steinbacher
- Proteros Biostructures GmbH , Bunsenstrasse 7a, D-82152 Martinsried, Germany
| | - Rachana Ohri
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Helga Raab
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Leanna R Staben
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Guiling Zhao
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - John A Flygare
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Thomas H Pillow
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Vishal Verma
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| | - Luke A Masterson
- Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, United Kingdom
| | - Philip W Howard
- Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, United Kingdom
| | - Brian Safina
- Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
68
|
Malik P, Phipps C, Edginton A, Blay J. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. Pharm Res 2017; 34:2579-2595. [PMID: 28924691 DOI: 10.1007/s11095-017-2259-3] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Accepted: 09/09/2017] [Indexed: 12/26/2022]
Abstract
Antibody-drug conjugates (ADCs) are ushering in the next era of targeted therapy against cancer. An ADC for cancer therapy consists of a potent cytotoxic payload that is attached to a tumour-targeted antibody by a chemical linker, usually with an average drug-to-antibody ratio (DAR) of 3.5-4. The theory is to deliver potent cytotoxic payloads directly to tumour cells while sparing healthy cells. However, practical application has proven to be more difficult. At present there are only two ADCs approved for clinical use. Nevertheless, in the last decade there has been an explosion of options for ADC engineering to optimize target selection, Fc receptor interactions, linker, payload and more. Evaluation of these strategies requires an understanding of the mechanistic underpinnings of ADC pharmacokinetics. Development of ADCs for use in cancer further requires an understanding of tumour properties and kinetics within the tumour environment, and how the presence of cancer as a disease will impact distribution and elimination. Key pharmacokinetic considerations for the successful design and clinical application of ADCs in oncology are explored in this review, with a focus on the mechanistic determinants of distribution and elimination.
Collapse
Affiliation(s)
- Paul Malik
- School of Pharmacy, University of Waterloo, 10A Victoria St South, Kitchener, Ontario, N2G 1C5, Canada
| | - Colin Phipps
- School of Pharmacy, University of Waterloo, 10A Victoria St South, Kitchener, Ontario, N2G 1C5, Canada.,DMPK & Translational Modeling, Abbvie Inc., North Chicago, Illinois, 60064, USA
| | - Andrea Edginton
- School of Pharmacy, University of Waterloo, 10A Victoria St South, Kitchener, Ontario, N2G 1C5, Canada.
| | - Jonathan Blay
- School of Pharmacy, University of Waterloo, 10A Victoria St South, Kitchener, Ontario, N2G 1C5, Canada
| |
Collapse
|
69
|
Acar H, Samaeekia R, Schnorenberg MR, Sasmal DK, Huang J, Tirrell MV, LaBelle JL. Cathepsin-Mediated Cleavage of Peptides from Peptide Amphiphiles Leads to Enhanced Intracellular Peptide Accumulation. Bioconjug Chem 2017; 28:2316-2326. [PMID: 28771332 DOI: 10.1021/acs.bioconjchem.7b00364] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Peptides synthesized in the likeness of their native interaction domain(s) are natural choices to target protein-protein interactions (PPIs) due to their fidelity of orthostatic contact points between binding partners. Despite therapeutic promise, intracellular delivery of biofunctional peptides at concentrations necessary for efficacy remains a formidable challenge. Peptide amphiphiles (PAs) provide a facile method of intracellular delivery and stabilization of bioactive peptides. PAs consisting of biofunctional peptide headgroups linked to hydrophobic alkyl lipid-like tails prevent peptide hydrolysis and proteolysis in circulation, and PA monomers are internalized via endocytosis. However, endocytotic sequestration and steric hindrance from the lipid tail are two major mechanisms that limit PA efficacy to target intracellular PPIs. To address these problems, we have constructed a PA platform consisting of cathepsin-B cleavable PAs in which a selective p53-based inhibitory peptide is cleaved from its lipid tail within endosomes, allowing for intracellular peptide accumulation and extracellular recycling of the lipid moiety. We monitor for cleavage and follow individual PA components in real time using a Förster resonance energy transfer (FRET)-based tracking system. Using this platform, we provide a better understanding and quantification of cellular internalization, trafficking, and endosomal cleavage of PAs and of the ultimate fates of each component.
Collapse
Affiliation(s)
- Handan Acar
- Institute for Molecular Engineering, University of Chicago, Eckardt Research Center , 5640 South Ellis Avenue, Chicago, Illinois 60637, United States.,Department of Pediatrics, Section of Hematology/Oncology, University of Chicago , 900 East 57th Street, KCBD 5122, Chicago, Illinois 60637, United States
| | - Ravand Samaeekia
- Institute for Molecular Engineering, University of Chicago, Eckardt Research Center , 5640 South Ellis Avenue, Chicago, Illinois 60637, United States.,Department of Pediatrics, Section of Hematology/Oncology, University of Chicago , 900 East 57th Street, KCBD 5122, Chicago, Illinois 60637, United States
| | - Mathew R Schnorenberg
- Institute for Molecular Engineering, University of Chicago, Eckardt Research Center , 5640 South Ellis Avenue, Chicago, Illinois 60637, United States.,Department of Pediatrics, Section of Hematology/Oncology, University of Chicago , 900 East 57th Street, KCBD 5122, Chicago, Illinois 60637, United States.,Medical Scientist Training Program, University of Chicago , 924 East 57th Street, Suite 104, Chicago, Illinois 60637, United States
| | - Dibyendu K Sasmal
- Institute for Molecular Engineering, University of Chicago, Eckardt Research Center , 5640 South Ellis Avenue, Chicago, Illinois 60637, United States
| | - Jun Huang
- Institute for Molecular Engineering, University of Chicago, Eckardt Research Center , 5640 South Ellis Avenue, Chicago, Illinois 60637, United States
| | - Matthew V Tirrell
- Institute for Molecular Engineering, University of Chicago, Eckardt Research Center , 5640 South Ellis Avenue, Chicago, Illinois 60637, United States.,Institute for Molecular Engineering, Argonne National Laboratory , 9700 South Cass Avenue, Argonne, Illinois 60639, United States
| | - James L LaBelle
- Department of Pediatrics, Section of Hematology/Oncology, University of Chicago , 900 East 57th Street, KCBD 5122, Chicago, Illinois 60637, United States
| |
Collapse
|
70
|
Grünewald J, Jin Y, Vance J, Read J, Wang X, Wan Y, Zhou H, Ou W, Klock HE, Peters EC, Uno T, Brock A, Geierstanger BH. Optimization of an Enzymatic Antibody-Drug Conjugation Approach Based on Coenzyme A Analogs. Bioconjug Chem 2017; 28:1906-1915. [PMID: 28590752 DOI: 10.1021/acs.bioconjchem.7b00236] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Phosphopantetheine transferases (PPTases) can be used to efficiently prepare site-specific antibody-drug conjugates (ADCs) by enzymatically coupling coenzyme A (CoA)-linker payloads to 11-12 amino acid peptide substrates inserted into antibodies. Here, a two-step strategy is established wherein in a first step, CoA analogs with various bioorthogonal reactivities are enzymatically installed on the antibody for chemical conjugation with a cytotoxic payload in a second step. Because of the high structural similarity of these CoA analogs to the natural PPTase substrate CoA-SH, the first step proceeds very efficiently and enables the use of peptide tags as short as 6 amino acids compared to the 11-12 amino acids required for efficient one-step coupling of the payload molecule. Furthermore, two-step conjugation provides access to diverse linker chemistries and spacers of varying lengths. The potency of the ADCs was largely independent of linker architecture. In mice, proteolytic cleavage was observed for some C-terminally linked auristatin payloads. The in vivo stability of these ADCs was significantly improved by reduction of the linker length. In addition, linker stability was found to be modulated by attachment site, and this, together with linker length, provides an opportunity for maximizing ADC stability without sacrificing potency.
Collapse
Affiliation(s)
- Jan Grünewald
- Genomics Institute of the Novartis Research Foundation (GNF) , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Yunho Jin
- Genomics Institute of the Novartis Research Foundation (GNF) , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Julie Vance
- Genomics Institute of the Novartis Research Foundation (GNF) , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Jessica Read
- Genomics Institute of the Novartis Research Foundation (GNF) , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Xing Wang
- Genomics Institute of the Novartis Research Foundation (GNF) , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Yongqin Wan
- Genomics Institute of the Novartis Research Foundation (GNF) , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Huanfang Zhou
- Genomics Institute of the Novartis Research Foundation (GNF) , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Weijia Ou
- Genomics Institute of the Novartis Research Foundation (GNF) , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Heath E Klock
- Genomics Institute of the Novartis Research Foundation (GNF) , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Eric C Peters
- Genomics Institute of the Novartis Research Foundation (GNF) , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Tetsuo Uno
- Genomics Institute of the Novartis Research Foundation (GNF) , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Ansgar Brock
- Genomics Institute of the Novartis Research Foundation (GNF) , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States
| | - Bernhard H Geierstanger
- Genomics Institute of the Novartis Research Foundation (GNF) , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States
| |
Collapse
|
71
|
Yin G, Stephenson HT, Yang J, Li X, Armstrong SM, Heibeck TH, Tran C, Masikat MR, Zhou S, Stafford RL, Yam AY, Lee J, Steiner AR, Gill A, Penta K, Pollitt S, Baliga R, Murray CJ, Thanos CD, McEvoy LM, Sato AK, Hallam TJ. RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates. Sci Rep 2017; 7:3026. [PMID: 28596531 PMCID: PMC5465077 DOI: 10.1038/s41598-017-03192-z] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Accepted: 04/27/2017] [Indexed: 11/12/2022] Open
Abstract
Amber codon suppression for the insertion of non-natural amino acids (nnAAs) is limited by competition with release factor 1 (RF1). Here we describe the genome engineering of a RF1 mutant strain that enhances suppression efficiency during cell-free protein synthesis, without significantly impacting cell growth during biomass production. Specifically, an out membrane protease (OmpT) cleavage site was engineered into the switch loop of RF1, which enables its conditional inactivation during cell lysis. This facilitates extract production without additional processing steps, resulting in a scaleable extract production process. The RF1 mutant extract allows nnAA incorporation at previously intractable sites of an IgG1 and at multiple sites in the same polypeptide chain. Conjugation of cytotoxic agents to these nnAAs, yields homogeneous antibody drug conjugates (ADCs) that can be optimized for conjugation site, drug to antibody ratio (DAR) and linker-warheads designed for efficient tumor killing. This platform provides the means to generate therapeutic ADCs inaccessible by other methods that are efficient in their cytotoxin delivery to tumor with reduced dose-limiting toxicities and thus have the potential for better clinical impact.
Collapse
Affiliation(s)
- Gang Yin
- Sutro Biopharma Inc, South San Francisco, CA, 94080, USA.
| | | | - Junhao Yang
- Sutro Biopharma Inc, South San Francisco, CA, 94080, USA
| | - Xiaofan Li
- Sutro Biopharma Inc, South San Francisco, CA, 94080, USA
| | | | | | - Cuong Tran
- Sutro Biopharma Inc, South San Francisco, CA, 94080, USA
| | | | - Sihong Zhou
- Sutro Biopharma Inc, South San Francisco, CA, 94080, USA
| | | | - Alice Y Yam
- Sutro Biopharma Inc, South San Francisco, CA, 94080, USA
| | - John Lee
- Sutro Biopharma Inc, South San Francisco, CA, 94080, USA
| | | | - Avinash Gill
- Sutro Biopharma Inc, South San Francisco, CA, 94080, USA
| | - Kalyani Penta
- Sutro Biopharma Inc, South San Francisco, CA, 94080, USA
| | - Sonia Pollitt
- Sutro Biopharma Inc, South San Francisco, CA, 94080, USA
| | - Ramesh Baliga
- Sutro Biopharma Inc, South San Francisco, CA, 94080, USA
| | | | | | | | - Aaron K Sato
- Sutro Biopharma Inc, South San Francisco, CA, 94080, USA
| | | |
Collapse
|
72
|
Catabolism of antibody drug conjugates and characterization methods. Bioorg Med Chem 2017; 25:2933-2945. [DOI: 10.1016/j.bmc.2017.04.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Revised: 03/30/2017] [Accepted: 04/05/2017] [Indexed: 11/21/2022]
|
73
|
Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate. PLoS One 2017; 12:e0178452. [PMID: 28558059 PMCID: PMC5448779 DOI: 10.1371/journal.pone.0178452] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2017] [Accepted: 05/12/2017] [Indexed: 11/19/2022] Open
Abstract
Antibody drug conjugates (ADCs) are no longer an unknown entity in the field of cancer therapy with the success of marketed ADCs like ADCETRIS and KADCYLA and numerous others advancing through clinical trials. The pursuit of novel cytotoxic payloads beyond the mictotubule inhibitors and DNA damaging agents has led us to the recent discovery of an mRNA splicing inhibitor, thailanstatin, as a potent ADC payload. In our previous work, we observed that the potency of this payload was uniquely tied to the method of conjugation, with lysine conjugates showing much superior potency as compared to cysteine conjugates. However, the ADC field is rapidly shifting towards site-specific ADCs due to their advantages in manufacturability, characterization and safety. In this work we report the identification of a highly efficacious site-specific thailanstatin ADC. The site of conjugation played a critical role on both the in vitro and in vivo potency of these ADCs. During the course of this study, we developed a novel methodology of loading a single site with multiple payloads using an in situ generated multi-drug carrying peptidic linker that allowed us to rapidly screen for optimal conjugation sites. Using this methodology, we were able to identify a double-cysteine mutant ADC delivering four-loaded thailanstatin that was very efficacious in a gastric cancer xenograft model at 3mg/kg and was also shown to be efficacious against T-DM1 resistant and MDR1 overexpressing tumor cell lines.
Collapse
|
74
|
Pabst M, McDowell W, Manin A, Kyle A, Camper N, De Juan E, Parekh V, Rudge F, Makwana H, Kantner T, Parekh H, Michelet A, Sheng X, Popa G, Tucker C, Khayrzad F, Pollard D, Kozakowska K, Resende R, Jenkins A, Simoes F, Morris D, Williams P, Badescu G, Baker MP, Bird M, Frigerio M, Godwin A. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates. J Control Release 2017; 253:160-164. [DOI: 10.1016/j.jconrel.2017.02.027] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2016] [Revised: 02/17/2017] [Accepted: 02/23/2017] [Indexed: 12/14/2022]
|
75
|
Newman DJ, Cragg GM. Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates. Mar Drugs 2017; 15:md15040099. [PMID: 28353637 PMCID: PMC5408245 DOI: 10.3390/md15040099] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Revised: 03/24/2017] [Accepted: 03/27/2017] [Indexed: 01/09/2023] Open
Abstract
In this review, we have attempted to describe all of the antibody–drug conjugates using a marine-derived compound as the “warhead”, that are currently in clinical trials as listed in the current version of the NIH clinical trials database (clinicaltrials.gov). In searching this database, we used the beta-test version currently available, as it permitted more specific search parameters, since the regular version did not always find trials that had been completed in the past with some agents. We also added small discussion sections on candidates that are still at the preclinical stage, including a derivative of diazonamide that has an unusual interaction with tubulin (DZ-23840), which may also be a potential warhead in the future.
Collapse
|
76
|
Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 2017; 16:315-337. [PMID: 28303026 DOI: 10.1038/nrd.2016.268] [Citation(s) in RCA: 1382] [Impact Index Per Article: 197.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncology therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clinical trials that are evaluating more than 60 further ADC candidates. The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody. Furthermore, lessons learned during the past decade are now being used in the development of third-generation ADCs. In this Review, we discuss strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues. The selection and engineering of antibodies for site-specific drug conjugation, which will result in higher homogeneity and increased stability, as well as the quest for new conjugation chemistries and mechanisms of action, are priorities in ADC research.
Collapse
Affiliation(s)
- Alain Beck
- Institut de Recherche Pierre Fabre, Centre d'Immunologie Pierre Fabre, 5 Avenue Napoleon III, 74160 Saint Julien en Genevois, France
| | - Liliane Goetsch
- Institut de Recherche Pierre Fabre, Centre d'Immunologie Pierre Fabre, 5 Avenue Napoleon III, 74160 Saint Julien en Genevois, France
| | - Charles Dumontet
- Cancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS, 69000 Lyon, France.,University of Lyon, 69000 Lyon, France.,Hospices Civils de Lyon, 69000 Lyon, France
| | - Nathalie Corvaïa
- Institut de Recherche Pierre Fabre, Centre d'Immunologie Pierre Fabre, 5 Avenue Napoleon III, 74160 Saint Julien en Genevois, France
| |
Collapse
|
77
|
Bruins JJ, Westphal AH, Albada B, Wagner K, Bartels L, Spits H, van Berkel WJH, van Delft FL. Inducible, Site-Specific Protein Labeling by Tyrosine Oxidation-Strain-Promoted (4 + 2) Cycloaddition. Bioconjug Chem 2017; 28:1189-1193. [PMID: 28263569 PMCID: PMC5399473 DOI: 10.1021/acs.bioconjchem.7b00046] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Genetically encoded tyrosine (Y-tag) can be utilized as a latent anchor for inducible and site-selective conjugation. Upon oxidation of tyrosine with mushroom tyrosinase, strain-promoted cycloaddition (SPOCQ) of the resulting 1,2-quinone with various bicyclo[6.1.0]nonyne (BCN) derivatives led to efficient conjugation. The method was applied for fluorophore labeling of laminarinase A and for the site-specific preparation of an antibody-drug conjugate.
Collapse
Affiliation(s)
| | | | | | - Koen Wagner
- AIMM Therapeutics , Meibergdreef 59, 1105 BA Amsterdam, The Netherlands
| | - Lina Bartels
- AIMM Therapeutics , Meibergdreef 59, 1105 BA Amsterdam, The Netherlands
| | - Hergen Spits
- AIMM Therapeutics , Meibergdreef 59, 1105 BA Amsterdam, The Netherlands
| | | | | |
Collapse
|
78
|
Stefan N, Gébleux R, Waldmeier L, Hell T, Escher M, Wolter FI, Grawunder U, Beerli RR. Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation. Mol Cancer Ther 2017; 16:879-892. [DOI: 10.1158/1535-7163.mct-16-0688] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Revised: 10/14/2016] [Accepted: 02/02/2017] [Indexed: 11/16/2022]
|
79
|
DeVay RM, Delaria K, Zhu G, Holz C, Foletti D, Sutton J, Bolton G, Dushin R, Bee C, Pons J, Rajpal A, Liang H, Shelton D, Liu SH, Strop P. Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates. Bioconjug Chem 2017; 28:1102-1114. [DOI: 10.1021/acs.bioconjchem.7b00013] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Rachel M. DeVay
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| | - Kathy Delaria
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| | - Guoyun Zhu
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| | - Charles Holz
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| | - Davide Foletti
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| | - Janette Sutton
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| | - Gary Bolton
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| | - Russell Dushin
- Worldwide
Medicinal Chemistry, Pfizer Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Christine Bee
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| | - Jaume Pons
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| | - Arvind Rajpal
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| | - Hong Liang
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| | - David Shelton
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| | - Shu-Hui Liu
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| | - Pavel Strop
- Rinat
Laboratories, Pfizer Inc., 230 East Grand Avenue, South
San Francisco, California 94080, United States
| |
Collapse
|
80
|
Gébleux R, Stringhini M, Casanova R, Soltermann A, Neri D. Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix. Int J Cancer 2016; 140:1670-1679. [PMID: 27943268 DOI: 10.1002/ijc.30569] [Citation(s) in RCA: 85] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Revised: 11/24/2016] [Accepted: 12/02/2016] [Indexed: 01/05/2023]
Abstract
Antibody-drug conjugates (ADCs) represent a promising class of biopharmaceuticals with the potential to localize at the tumor site and improve the therapeutic index of cytotoxic drugs. While it is generally believed that ADCs need to be internalized into tumor cells in order to display optimal therapeutic activity, it has recently been shown that non-internalizing antibodies can efficiently liberate disulfide-linked drugs at the extracellular tumor site, leading to potent anti-cancer activity in preclinical animal models. Here, we show that engineered variants of the F16 antibody, specific to a splice isoform of tenascin-C, selectively localize to the subendothelial tumor extracellular matrix in three mouse models of human cancer (U87, A431, MDA-MB-231). A site-specific coupling of F16 in IgG format with a monomethyl auristatin E (MMAE) derivative, featuring a valine-citrulline dipeptide linker equipped with a self-immolative spacer, yielded an ADC product, which cured tumor-bearing mice at a dose of 7 mg/Kg. The observation of an efficient extracellular proteolytic cleavage of the valine-citrulline linker was surprising, as it has generally been assumed that this peptidic structure would be selectively cleaved by cathepsin B in intracellular compartments. The products described in this article may be useful for the treatment of human malignancies, as their cognate antigen is strongly expressed in the majority of human solid tumors, lymphomas and aggressive leukemias, while being virtually undetectable in most normal adult tissues.
Collapse
Affiliation(s)
- Rémy Gébleux
- Department of Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zürich, CH-8093, Switzerland
| | - Marco Stringhini
- Department of Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zürich, CH-8093, Switzerland
| | - Ruben Casanova
- Institute of Pathology, University Hospital Zurich, Zurich, CH-8091, Switzerland
| | - Alex Soltermann
- Institute of Pathology, University Hospital Zurich, Zurich, CH-8091, Switzerland
| | - Dario Neri
- Department of Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zürich, CH-8093, Switzerland
| |
Collapse
|
81
|
Su D, Ng C, Khosraviani M, Yu SF, Cosino E, Kaur S, Xu K. Custom-Designed Affinity Capture LC-MS F(ab′)2 Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates. Anal Chem 2016; 88:11340-11346. [DOI: 10.1021/acs.analchem.6b03410] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Dian Su
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Carl Ng
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | | | - Shang-Fan Yu
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Ely Cosino
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Surinder Kaur
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Keyang Xu
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
82
|
Tumey LN, Leverett CA, Vetelino B, Li F, Rago B, Han X, Loganzo F, Musto S, Bai G, Sukuru SCK, Graziani EI, Puthenveetil S, Casavant J, Ratnayake A, Marquette K, Hudson S, Doppalapudi VR, Stock J, Tchistiakova L, Bessire AJ, Clark T, Lucas J, Hosselet C, O’Donnell CJ, Subramanyam C. Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism. ACS Med Chem Lett 2016; 7:977-982. [PMID: 27882194 PMCID: PMC5108037 DOI: 10.1021/acsmedchemlett.6b00195] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Accepted: 06/22/2016] [Indexed: 01/19/2023] Open
Abstract
As part of our efforts to develop new classes of tubulin inhibitor payloads for antibody-drug conjugate (ADC) programs, we developed a tubulysin ADC that demonstrated excellent in vitro activity but suffered from rapid metabolism of a critical acetate ester. A two-pronged strategy was employed to address this metabolism. First, the hydrolytically labile ester was replaced by a carbamate functional group resulting in a more stable ADC that retained potency in cellular assays. Second, site-specific conjugation was employed in order to design ADCs with reduced metabolic liabilities. Using the later approach, we were able to identify a conjugate at the 334C position of the heavy chain that resulted in an ADC with considerably reduced metabolism and improved efficacy. The examples discussed herein provide one of the clearest demonstrations to-date that site of conjugation can play a critical role in addressing metabolic and PK liabilities of an ADC. Moreover, a clear correlation was identified between the hydrophobicity of an ADC and its susceptibility to metabolic enzymes. Importantly, this study demonstrates that traditional medicinal chemistry strategies can be effectively applied to ADC programs.
Collapse
Affiliation(s)
- L. Nathan Tumey
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Carolyn A. Leverett
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Beth Vetelino
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Fengping Li
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Brian Rago
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Xiaogang Han
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Frank Loganzo
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Sylvia Musto
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Guoyun Bai
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | | | - Edmund I. Graziani
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Sujiet Puthenveetil
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Jeffrey Casavant
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Anokha Ratnayake
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Kimberly Marquette
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Sarah Hudson
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | | | - Joseph Stock
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | | | - Andrew J. Bessire
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Tracey Clark
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Judy Lucas
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Christine Hosselet
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | | | | |
Collapse
|
83
|
Shim MK, Yoon HY, Ryu JH, Koo H, Lee S, Park JH, Kim JH, Lee S, Pomper MG, Kwon IC, Kim K. Cathepsin B-Specific Metabolic Precursor for In Vivo Tumor-Specific Fluorescence Imaging. Angew Chem Int Ed Engl 2016. [DOI: 10.1002/ange.201608504] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Man Kyu Shim
- Center for Theragnosis, Biomedical Research Institute; Korea Institute of Science and Technology; 5, Hwarang-ro 14-gil Seongbuk-gu Seoul 02792 Republic of Korea
- Department of Pharmacy, Graduate School; Kyung Hee University; 26, Kyungheedae-ro Dongdaemun-gu Seoul 02447 Republic of Korea
| | - Hong Yeol Yoon
- Center for Theragnosis, Biomedical Research Institute; Korea Institute of Science and Technology; 5, Hwarang-ro 14-gil Seongbuk-gu Seoul 02792 Republic of Korea
- School of Chemical Engineering; Sungkyunkwan University; 2066, Seobu-ro Jangan-gu Suwon 16419 Republic of Korea
| | - Ju Hee Ryu
- Center for Theragnosis, Biomedical Research Institute; Korea Institute of Science and Technology; 5, Hwarang-ro 14-gil Seongbuk-gu Seoul 02792 Republic of Korea
| | - Heebeom Koo
- Department of Medical Life Science, College of Medicine; The Catholic University of Korea; 222, Banpo-daero Seocho-gu Seoul 06591 Republic of Korea
| | - Sangmin Lee
- Center for Theragnosis, Biomedical Research Institute; Korea Institute of Science and Technology; 5, Hwarang-ro 14-gil Seongbuk-gu Seoul 02792 Republic of Korea
- The Russell H. Morgan Department of Radiology and Radiological Science; Johns Hopkins University School of Medicine; 601 N. Caroline Street Baltimore MD 21287 USA
| | - Jae Hyung Park
- School of Chemical Engineering; Sungkyunkwan University; 2066, Seobu-ro Jangan-gu Suwon 16419 Republic of Korea
| | - Jong-Ho Kim
- Department of Pharmacy, Graduate School; Kyung Hee University; 26, Kyungheedae-ro Dongdaemun-gu Seoul 02447 Republic of Korea
| | - Seulki Lee
- The Russell H. Morgan Department of Radiology and Radiological Science; Johns Hopkins University School of Medicine; 601 N. Caroline Street Baltimore MD 21287 USA
| | - Martin G. Pomper
- The Russell H. Morgan Department of Radiology and Radiological Science; Johns Hopkins University School of Medicine; 601 N. Caroline Street Baltimore MD 21287 USA
| | - Ick Chan Kwon
- Center for Theragnosis, Biomedical Research Institute; Korea Institute of Science and Technology; 5, Hwarang-ro 14-gil Seongbuk-gu Seoul 02792 Republic of Korea
- KU-KIST Graduate School of Converging Science and Technology; Korea University; 145 Anam-ro Seongbuk-gu Seoul 02841 Republic of Korea
| | - Kwangmeyung Kim
- Center for Theragnosis, Biomedical Research Institute; Korea Institute of Science and Technology; 5, Hwarang-ro 14-gil Seongbuk-gu Seoul 02792 Republic of Korea
| |
Collapse
|
84
|
Shim MK, Yoon HY, Ryu JH, Koo H, Lee S, Park JH, Kim J, Lee S, Pomper MG, Kwon IC, Kim K. Cathepsin B‐Specific Metabolic Precursor for In Vivo Tumor‐Specific Fluorescence Imaging. Angew Chem Int Ed Engl 2016; 55:14698-14703. [DOI: 10.1002/anie.201608504] [Citation(s) in RCA: 67] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Indexed: 01/08/2023]
Affiliation(s)
- Man Kyu Shim
- Center for Theragnosis, Biomedical Research Institute Korea Institute of Science and Technology 5, Hwarang-ro 14-gil Seongbuk-gu Seoul 02792 Republic of Korea
- Department of Pharmacy, Graduate School Kyung Hee University 26, Kyungheedae-ro Dongdaemun-gu Seoul 02447 Republic of Korea
| | - Hong Yeol Yoon
- Center for Theragnosis, Biomedical Research Institute Korea Institute of Science and Technology 5, Hwarang-ro 14-gil Seongbuk-gu Seoul 02792 Republic of Korea
- School of Chemical Engineering Sungkyunkwan University 2066, Seobu-ro Jangan-gu Suwon 16419 Republic of Korea
| | - Ju Hee Ryu
- Center for Theragnosis, Biomedical Research Institute Korea Institute of Science and Technology 5, Hwarang-ro 14-gil Seongbuk-gu Seoul 02792 Republic of Korea
| | - Heebeom Koo
- Department of Medical Life Science, College of Medicine The Catholic University of Korea 222, Banpo-daero Seocho-gu Seoul 06591 Republic of Korea
| | - Sangmin Lee
- Center for Theragnosis, Biomedical Research Institute Korea Institute of Science and Technology 5, Hwarang-ro 14-gil Seongbuk-gu Seoul 02792 Republic of Korea
- The Russell H. Morgan Department of Radiology and Radiological Science Johns Hopkins University School of Medicine 601 N. Caroline Street Baltimore MD 21287 USA
| | - Jae Hyung Park
- School of Chemical Engineering Sungkyunkwan University 2066, Seobu-ro Jangan-gu Suwon 16419 Republic of Korea
| | - Jong‐Ho Kim
- Department of Pharmacy, Graduate School Kyung Hee University 26, Kyungheedae-ro Dongdaemun-gu Seoul 02447 Republic of Korea
| | - Seulki Lee
- The Russell H. Morgan Department of Radiology and Radiological Science Johns Hopkins University School of Medicine 601 N. Caroline Street Baltimore MD 21287 USA
| | - Martin G. Pomper
- The Russell H. Morgan Department of Radiology and Radiological Science Johns Hopkins University School of Medicine 601 N. Caroline Street Baltimore MD 21287 USA
| | - Ick Chan Kwon
- Center for Theragnosis, Biomedical Research Institute Korea Institute of Science and Technology 5, Hwarang-ro 14-gil Seongbuk-gu Seoul 02792 Republic of Korea
- KU-KIST Graduate School of Converging Science and Technology Korea University 145 Anam-ro Seongbuk-gu Seoul 02841 Republic of Korea
| | - Kwangmeyung Kim
- Center for Theragnosis, Biomedical Research Institute Korea Institute of Science and Technology 5, Hwarang-ro 14-gil Seongbuk-gu Seoul 02792 Republic of Korea
| |
Collapse
|
85
|
Strop P, Tran TT, Dorywalska M, Delaria K, Dushin R, Wong OK, Ho WH, Zhou D, Wu A, Kraynov E, Aschenbrenner L, Han B, O'Donnell CJ, Pons J, Rajpal A, Shelton DL, Liu SH. RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models. Mol Cancer Ther 2016; 15:2698-2708. [PMID: 27582525 DOI: 10.1158/1535-7163.mct-16-0431] [Citation(s) in RCA: 69] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Accepted: 08/12/2016] [Indexed: 11/16/2022]
Abstract
Trop-2, also known as TACSTD2, EGP-1, GA733-1, and M1S1, is frequently expressed on a variety of human carcinomas, and its expression is often associated with poor prognosis of the diseases. However, it is also present on the epithelium of several normal tissues. A comprehensively designed Trop-2-targeting antibody-drug conjugate (ADC), balancing both efficacy and toxicity, is therefore necessary to achieve clinical utility. To this end, we developed a cleavable Trop-2 ADC (RN927C) using a site-specific transglutaminase-mediated conjugation method and a proprietary microtubule inhibitor (MTI) linker-payload, PF-06380101. Robust in vitro cytotoxicity of RN927C was observed on a panel of Trop-2-expressing tumor cell lines, with IC50 generally in the subnanomolar range. As expected for an MTI-containing ADC, RN927C readily induced mitotic arrest of treated cells in vitro and in vivo, followed by subsequent cell death. The in vivo efficacy of RN927C was tested in multiple cell line and patient-derived xenograft tumor models, including pancreatic, lung, ovarian, and triple-negative breast tumor types. Single-dose administration of RN927C at 0.75 to 3 mg/kg was generally sufficient to induce sustained regression of Trop-2-expressing tumors and showed superior efficacy over standard treatment with paclitaxel or gemcitabine. Administration of RN927C in nonhuman primate toxicity studies resulted in target-mediated effects in skin and oral mucosa, consistent with Trop-2 expression in these epithelial tissues with minimal, non-dose limiting off-target toxicities. On the basis of the combined efficacy and safety results, RN927C is postulated to have a favorable therapeutic index for treatment of solid tumors. Mol Cancer Ther; 15(11); 2698-708. ©2016 AACR.
Collapse
Affiliation(s)
- Pavel Strop
- Oncology-Rinat R&D, Pfizer Inc., South San Francisco, California
| | - Thomas-Toan Tran
- Oncology-Rinat R&D, Pfizer Inc., South San Francisco, California
| | | | - Kathy Delaria
- Oncology-Rinat R&D, Pfizer Inc., South San Francisco, California
| | - Russell Dushin
- Worldwide Medicinal Chemistry, Pfizer Inc., Groton, Connecticut
| | - Oi Kwan Wong
- Oncology-Rinat R&D, Pfizer Inc., South San Francisco, California
| | - Wei-Hsien Ho
- Oncology-Rinat R&D, Pfizer Inc., South San Francisco, California
| | - Dahui Zhou
- Worldwide Medicinal Chemistry, Pfizer Inc., Groton, Connecticut
| | - Aidong Wu
- Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc., San Diego, California
| | - Eugenia Kraynov
- Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc., San Diego, California
| | | | - Bora Han
- Drug Safety R&D, Pfizer Inc., San Diego, California
| | | | - Jaume Pons
- Oncology-Rinat R&D, Pfizer Inc., South San Francisco, California
| | - Arvind Rajpal
- Oncology-Rinat R&D, Pfizer Inc., South San Francisco, California
| | - Dave L Shelton
- Oncology-Rinat R&D, Pfizer Inc., South San Francisco, California
| | - Shu-Hui Liu
- Oncology-Rinat R&D, Pfizer Inc., South San Francisco, California.
| |
Collapse
|
86
|
|
87
|
Gorka AP, Schnermann MJ. Harnessing cyanine photooxidation: from slowing photobleaching to near-IR uncaging. Curr Opin Chem Biol 2016; 33:117-25. [PMID: 27348157 DOI: 10.1016/j.cbpa.2016.05.022] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Revised: 05/23/2016] [Accepted: 05/24/2016] [Indexed: 01/09/2023]
Abstract
Light provides a uniquely powerful stimulus to help visualize and/or perturb biological systems. The use of tissue penetrant near-IR wavelengths enables in vivo applications, however the design of molecules that function in this range remains a substantial challenge. Heptamethine cyanine fluorophores are already important tools for near-IR optical imaging. These molecules are susceptible to photobleaching through a photooxidative cleavage reaction. This review details efforts to define the mechanism of this reaction and two emerging fields closely tied to this process. In the first, efforts that slow photooxidation enable the creation of photobleaching resistant fluorophores. In the second, cyanine photooxidation has recently been employed as the cornerstone of a near-IR uncaging strategy. This review seeks to highlight the utility of mechanistic organic chemistry insights to help tailor cyanine scaffolds for new, and previously intractable, biological applications.
Collapse
Affiliation(s)
- Alexander P Gorka
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA
| | - Martin J Schnermann
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
| |
Collapse
|
88
|
Lühmann T, Meinel L. Nanotransporters for drug delivery. Curr Opin Biotechnol 2016; 39:35-40. [DOI: 10.1016/j.copbio.2015.12.013] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2015] [Accepted: 12/19/2015] [Indexed: 01/02/2023]
|
89
|
Bellat V, Lee HH, Vahdat L, Law B. Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties. Biomacromolecules 2016; 17:2040-9. [PMID: 27180972 DOI: 10.1021/acs.biomac.6b00227] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We previously reported a high aspect ratio peptide nanofiber that could be effectively delivered to tumors with minimal nonspecific uptake by other organs. The peptidic nature offers the design flexibility of smart formulation with unique responsiveness. Two new formulations that behave congruously as nanotransformers (NTFs) are reported herein. NTF1 and NTF2 could biomechanically remodel upon enzyme activation to generate a degradable and an aggregable effect, respectively, within the lysosomal compartment. These NTFs were further evaluated as carriers of mertansine (DM1), a microtubule inhibitor. DM1-loaded NTF1 could be degraded by cathepsin B (CathB) to release the same active metabolite, as previously described in the lysosomal degradation of antibody-DM1 conjugate. In contrast, CathB only partially digested DM1-loaded NTF2 and induced aggregate formation to become a storage reservoir with slow payload release property. The DM1-loaded NTF1 exhibited a comparable cytotoxicity to the free drug and was more effective than the NTF2 formulation in eradicating triple negative breast cancer. Our data suggested that biological transformers with distinct enzyme-induced structural changes and payload release profiles could be designed for the intracellular delivery of cytotoxic and imaging agents.
Collapse
Affiliation(s)
- Vanessa Bellat
- Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine , 413 East 69th Street, New York, New York 10021, United States
| | - Hyun Hee Lee
- Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine , 413 East 69th Street, New York, New York 10021, United States
| | - Linda Vahdat
- Department of Medicine, Weill Cornell Medicine , 425 East 61st Street, New York, New York 10065, United States
| | - Benedict Law
- Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine , 413 East 69th Street, New York, New York 10021, United States
| |
Collapse
|
90
|
Massa S, Xavier C, Muyldermans S, Devoogdt N. Emerging site-specific bioconjugation strategies for radioimmunotracer development. Expert Opin Drug Deliv 2016; 13:1149-63. [DOI: 10.1080/17425247.2016.1178235] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Sam Massa
- In vivo Cellular and Molecular Imaging laboratory, Vrije Universiteit Brussel (VUB), Brussels, Belgium
- Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium
| | - Catarina Xavier
- In vivo Cellular and Molecular Imaging laboratory, Vrije Universiteit Brussel (VUB), Brussels, Belgium
| | - Serge Muyldermans
- Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium
| | - Nick Devoogdt
- In vivo Cellular and Molecular Imaging laboratory, Vrije Universiteit Brussel (VUB), Brussels, Belgium
- Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium
| |
Collapse
|
91
|
Huang RYC, Chen G. Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends. Drug Discov Today 2016; 21:850-5. [PMID: 27080148 DOI: 10.1016/j.drudis.2016.04.004] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Revised: 03/16/2016] [Accepted: 04/05/2016] [Indexed: 12/31/2022]
Abstract
Antibody-drug conjugates (ADCs) are emerging modalities in the pharmaceutical industry. The unique target-specific binding of antibody allows targeted delivery of cytotoxic small molecules to cancer cells, and thus expands the therapeutic window. However, in-depth characterization of ADCs is complex because it involves the characterization of antibody, conjugated molecules and antibody conjugates as a whole. In this review, we describe the practical use of mass spectrometry for ADC characterization including qualitative and quantitative analysis. Technical advances, limitations and future trends will also be discussed.
Collapse
Affiliation(s)
- Richard Y-C Huang
- Bioanalytical and Discovery Analytical Sciences, Research and Development, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ 08543, USA
| | - Guodong Chen
- Bioanalytical and Discovery Analytical Sciences, Research and Development, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ 08543, USA.
| |
Collapse
|
92
|
Puthenveetil S, Musto S, Loganzo F, Tumey LN, O'Donnell CJ, Graziani E. Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates. Bioconjug Chem 2016; 27:1030-9. [PMID: 26942771 DOI: 10.1021/acs.bioconjchem.6b00054] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The focus of the antibody-drug conjugate (ADC) field is shifting toward development of site-specific, next-generation ADCs to address the issue of heterogeneity, metabolic instability, conjugatability, and less than ideal therapeutic index associated with the conventional (heterogeneous) ADCs. It is evident from the recent literature that the site of conjugation, the structure of the linker, and the physicochemical properties of the linker-payload all have a significant impact on the safety and efficacy of the resulting ADCs. Screening multiple linker-payloads on multiple sites of an antibody presents a combinatorial problem that necessitates high-throughput conjugation and purification methodology to identify ADCs with the best combination of site and payload. Toward this end, we developed a protein A/L-based solid-phase, site-specific conjugation and purification method that can be used to generate site-specific ADCs in a 96-well plate format. This solid-phase method has been shown to be versatile because of its compatibility with various conjugation functional handles such as maleimides, haloacetamides, copper free click substrates, and transglutaminase substrates. The application of this methodology was further expanded to generate dual labeled, site-specific antibody and Fab conjugates.
Collapse
Affiliation(s)
- Sujiet Puthenveetil
- Worldwide Medicinal Chemistry, Pfizer Global R&D , Groton, Connecticut 06340, United States
| | - Sylvia Musto
- Pfizer Oncology-Rinat R&D , 401 North Middletown Road, Pearl River, New York 10965, United States
| | - Frank Loganzo
- Pfizer Oncology-Rinat R&D , 401 North Middletown Road, Pearl River, New York 10965, United States
| | - L Nathan Tumey
- Worldwide Medicinal Chemistry, Pfizer Global R&D , Groton, Connecticut 06340, United States
| | | | - Edmund Graziani
- Worldwide Medicinal Chemistry, Pfizer Global R&D , Groton, Connecticut 06340, United States
| |
Collapse
|
93
|
Dorywalska M, Dushin R, Moine L, Farias SE, Zhou D, Navaratnam T, Lui V, Hasa-Moreno A, Casas MG, Tran TT, Delaria K, Liu SH, Foletti D, O'Donnell CJ, Pons J, Shelton DL, Rajpal A, Strop P. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design. Mol Cancer Ther 2016; 15:958-70. [PMID: 26944918 DOI: 10.1158/1535-7163.mct-15-1004] [Citation(s) in RCA: 130] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Accepted: 02/12/2016] [Indexed: 11/16/2022]
Abstract
The degree of stability of antibody-drug linkers in systemic circulation, and the rate of their intracellular processing within target cancer cells are among the key factors determining the efficacy of antibody-drug conjugates (ADC) in vivo Previous studies demonstrated the susceptibility of cleavable linkers, as well as auristatin-based payloads, to enzymatic cleavage in rodent plasma. Here, we identify Carboxylesterase 1C as the enzyme responsible for the extracellular hydrolysis of valine-citrulline-p-aminocarbamate (VC-PABC)-based linkers in mouse plasma. We further show that the activity of Carboxylesterase 1C towards VC-PABC-based linkers, and consequently the stability of ADCs in mouse plasma, can be effectively modulated by small chemical modifications to the linker. While the introduced modifications can protect the VC-PABC-based linkers from extracellular cleavage, they do not significantly alter the intracellular linker processing by the lysosomal protease Cathepsin B. The distinct substrate preference of the serum Carboxylesterase 1C offers the opportunity to modulate the extracellular stability of cleavable ADCs without diminishing the intracellular payload release required for ADC efficacy. Mol Cancer Ther; 15(5); 958-70. ©2016 AACR.
Collapse
Affiliation(s)
| | - Russell Dushin
- Worldwide Medicinal Chemistry, Pfizer Inc., Groton, Connecticut
| | - Ludivine Moine
- Worldwide Medicinal Chemistry, Pfizer Inc., Groton, Connecticut
| | | | - Dahui Zhou
- Worldwide Medicinal Chemistry, Pfizer Inc., Groton, Connecticut
| | | | - Victor Lui
- Rinat Laboratories, Pfizer Inc., South San Francisco, California
| | | | | | - Thomas-Toan Tran
- Rinat Laboratories, Pfizer Inc., South San Francisco, California
| | - Kathy Delaria
- Rinat Laboratories, Pfizer Inc., South San Francisco, California
| | - Shu-Hui Liu
- Rinat Laboratories, Pfizer Inc., South San Francisco, California
| | - Davide Foletti
- Rinat Laboratories, Pfizer Inc., South San Francisco, California
| | | | - Jaume Pons
- Rinat Laboratories, Pfizer Inc., South San Francisco, California
| | - David L Shelton
- Rinat Laboratories, Pfizer Inc., South San Francisco, California
| | - Arvind Rajpal
- Rinat Laboratories, Pfizer Inc., South San Francisco, California
| | - Pavel Strop
- Rinat Laboratories, Pfizer Inc., South San Francisco, California.
| |
Collapse
|
94
|
Beck A, Terral G, Debaene F, Wagner-Rousset E, Marcoux J, Janin-Bussat MC, Colas O, Van Dorsselaer A, Cianférani S. Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. Expert Rev Proteomics 2016; 13:157-83. [PMID: 26653789 DOI: 10.1586/14789450.2016.1132167] [Citation(s) in RCA: 86] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Antibody drug conjugates (ADCs) are highly cytotoxic drugs covalently attached via conditionally stable linkers to monoclonal antibodies (mAbs) and are among the most promising next-generation empowered biologics for cancer treatment. ADCs are more complex than naked mAbs, as the heterogeneity of the conjugates adds to the inherent microvariability of the biomolecules. The development and optimization of ADCs rely on improving their analytical and bioanalytical characterization by assessing several critical quality attributes, namely the distribution and position of the drug, the amount of naked antibody, the average drug to antibody ratio, and the residual drug-linker and related product proportions. Here brentuximab vedotin (Adcetris) and trastuzumab emtansine (Kadcyla), the first and gold-standard hinge-cysteine and lysine drug conjugates, respectively, were chosen to develop new mass spectrometry (MS) methods and to improve multiple-level structural assessment protocols.
Collapse
Affiliation(s)
- Alain Beck
- a Centre d'Immunologie Pierre-Fabre (CIPF) , Saint-Julien-en-Genevois , France
| | - Guillaume Terral
- b BioOrganic Mass Spectrometry Laboratory (LSMBO), IPHC, Analytical Sciences Department , Université de Strasbourg , Strasbourg , France.,c IPHC, Analytical Sciences Department, CNRS, UMR7178 , Strasbourg , France
| | - François Debaene
- b BioOrganic Mass Spectrometry Laboratory (LSMBO), IPHC, Analytical Sciences Department , Université de Strasbourg , Strasbourg , France.,c IPHC, Analytical Sciences Department, CNRS, UMR7178 , Strasbourg , France
| | - Elsa Wagner-Rousset
- a Centre d'Immunologie Pierre-Fabre (CIPF) , Saint-Julien-en-Genevois , France
| | - Julien Marcoux
- b BioOrganic Mass Spectrometry Laboratory (LSMBO), IPHC, Analytical Sciences Department , Université de Strasbourg , Strasbourg , France.,c IPHC, Analytical Sciences Department, CNRS, UMR7178 , Strasbourg , France
| | | | - Olivier Colas
- a Centre d'Immunologie Pierre-Fabre (CIPF) , Saint-Julien-en-Genevois , France
| | - Alain Van Dorsselaer
- b BioOrganic Mass Spectrometry Laboratory (LSMBO), IPHC, Analytical Sciences Department , Université de Strasbourg , Strasbourg , France.,c IPHC, Analytical Sciences Department, CNRS, UMR7178 , Strasbourg , France
| | - Sarah Cianférani
- b BioOrganic Mass Spectrometry Laboratory (LSMBO), IPHC, Analytical Sciences Department , Université de Strasbourg , Strasbourg , France.,c IPHC, Analytical Sciences Department, CNRS, UMR7178 , Strasbourg , France
| |
Collapse
|
95
|
Tian M, Cheng R, Zhang J, Liu Z, Liu Z, Jiang J. Amphiphilic Polymer Micellar Disruption Based on Main-Chain Photodegradation. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2016; 32:12-18. [PMID: 26641733 DOI: 10.1021/acs.langmuir.5b03856] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The amphiphilic block copolymer poly(ethylene oxide)-b-poly(N,N'-dihydroxypyromellitimide-hexamethylene diisocyanate) (PEO-b-PNH) with photocleavable N-O urethanes has been prepared to investigate the photodegradation of the hydrophobic main chain and therefore the disruption of copolymer micelles. Measurements of absorption and emission spectra, optical transmittance, DLS analysis, and TEM observations were applied. It was shown that PEO-b-PNH could self-assemble into flower compound micelles in water. The photodegradation of the hydrophobic polyurethane within the micellar core upon irradiation with 365 nm light could be conveniently controlled by changing the irradiation intensity; furthermore, complete micellar disruption could be achieved when 42% of N-O urethanes were photocleaved. By using DOX as the hydrophobic guest, the drug release profile showed a linear leakage of DOX out of the swelling polymer micelles in the initial stage and thereafter a much more quick exponential decay of DOX precipitation because of the micellar disruption upon further irradiation. The diffusion experiment of the leaked DOX into buffer solution (pH 7.4) showed that the DOX leakage could be prominently accelerated by a very short time of 365 nm irradiation, indicating that the N-O photocleavage can serve as a "turn-on" switch for the release of DOX in aqueous media.
Collapse
Affiliation(s)
- Min Tian
- Key Laboratory of Applied Surface and Colloid Chemistry, Ministry of Education, School of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an, Shaanxi 710062, China
| | - Ruidong Cheng
- Key Laboratory of Applied Surface and Colloid Chemistry, Ministry of Education, School of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an, Shaanxi 710062, China
| | - Jun Zhang
- Key Laboratory of Applied Surface and Colloid Chemistry, Ministry of Education, School of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an, Shaanxi 710062, China
| | - Zhaotie Liu
- Key Laboratory of Applied Surface and Colloid Chemistry, Ministry of Education, School of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an, Shaanxi 710062, China
| | - Zhongwen Liu
- Key Laboratory of Applied Surface and Colloid Chemistry, Ministry of Education, School of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an, Shaanxi 710062, China
| | - Jinqiang Jiang
- Key Laboratory of Applied Surface and Colloid Chemistry, Ministry of Education, School of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an, Shaanxi 710062, China
| |
Collapse
|
96
|
Rickert M, Strop P, Lui V, Melton-Witt J, Farias SE, Foletti D, Shelton D, Pons J, Rajpal A. Production of soluble and active microbial transglutaminase in Escherichia coli for site-specific antibody drug conjugation. Protein Sci 2015; 25:442-55. [PMID: 26481561 DOI: 10.1002/pro.2833] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2015] [Revised: 10/06/2015] [Accepted: 10/19/2015] [Indexed: 11/11/2022]
Abstract
Applications of microbial transglutaminase (mTGase) produced from Streptomyces mobarensis (S. mobarensis) were recently extended from food to pharmaceutical industry. To use mTGase for clinical applications, like generation of site specific antibody drug conjugates, it would be beneficial to manufacture mTGase in Escherichia coli (E. coli). To date, attempts to express recombinant soluble and active S. mobarensis mTGase have been largely unsuccessful. mTGase from S. mobarensis is naturally expressed as proenzyme and stepwise proteolytically processed into its active mature form outside of the bacterial cell. The pro-domain is essential for correct folding of mTGase as well as for inhibiting activity of mTGase inside the cell. Here, we report a genetically modified mTGase that has full activity and can be expressed at high yields in the cytoplasm of E. coli. To achieve this we performed an alanine-scan of the mTGase pro-domain and identified mutants that maintain its chaperone function but destabilize the cleaved pro-domain/mTGase interaction in a temperature dependent fashion. This allows proper folding of mTGase and keeps the enzyme inactive during expression at 20°C, but results in full activity when shifted to 37°C due to loosen domain interactions. The insertion of the 3C protease cleavage site together with pro-domain alanine mutants Tyr14, Ile24, or Asn25 facilitate high yields (30-75 mg/L), and produced an enzyme with activity identical to wild type mTGase from S. mobarensis. Site-specific antibody drug conjugates made with the E .coli produced mTGase demonstrated identical potency in an in vitro cell assay to those made with mTGase from S. mobarensis.
Collapse
Affiliation(s)
- Mathias Rickert
- Rinat Laboratories, Pfizer, Inc, 230 East Grand Avenue, South San Francisco, California, 94080, USA
| | - Pavel Strop
- Rinat Laboratories, Pfizer, Inc, 230 East Grand Avenue, South San Francisco, California, 94080, USA
| | - Victor Lui
- Rinat Laboratories, Pfizer, Inc, 230 East Grand Avenue, South San Francisco, California, 94080, USA
| | - Jody Melton-Witt
- Rinat Laboratories, Pfizer, Inc, 230 East Grand Avenue, South San Francisco, California, 94080, USA
| | - Santiago Esteban Farias
- Rinat Laboratories, Pfizer, Inc, 230 East Grand Avenue, South San Francisco, California, 94080, USA
| | - Davide Foletti
- Rinat Laboratories, Pfizer, Inc, 230 East Grand Avenue, South San Francisco, California, 94080, USA
| | | | - Jaume Pons
- Rinat Laboratories, Pfizer, Inc, 230 East Grand Avenue, South San Francisco, California, 94080, USA
| | - Arvind Rajpal
- Rinat Laboratories, Pfizer, Inc, 230 East Grand Avenue, South San Francisco, California, 94080, USA
| |
Collapse
|
97
|
Antibody-conjugated drug assay for protease-cleavable antibody-drug conjugates. Bioanalysis 2015; 8:55-63. [PMID: 26647801 DOI: 10.4155/bio.15.230] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
BACKGROUND Antibody-drug conjugates (ADCs) require multiple assays to characterize their PK. These assays can separately evaluate the ADC by quantifying the antibody or the conjugated drug and may give different answers due to assay measurement differences, heterogeneous nature of ADCs and potential biotransformations that occur in vivo. RESULTS We present a new version of the antibody-conjugated drug assay for valine-citrulline-linked monomethylauristatin E (vcMMAE) ADCs. A stable isotope-labeled internal standard, protein A affinity capture and solid-phase cleavage of MMAE using papain was used prior to LC-MS/MS analysis. CONCLUSION The assay was used to assess the difference in ex vivo drug-linker stability of native-cysteine versus engineered cysteine ADCs and to determine the number of drugs per antibody of a native-cysteine ADC in vivo.
Collapse
|
98
|
Nani RR, Gorka AP, Nagaya T, Kobayashi H, Schnermann MJ. Near-IR Light-Mediated Cleavage of Antibody-Drug Conjugates Using Cyanine Photocages. Angew Chem Int Ed Engl 2015; 54:13635-8. [PMID: 26403799 DOI: 10.1002/anie.201507391] [Citation(s) in RCA: 129] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2015] [Indexed: 12/31/2022]
Abstract
Despite significant progress in the clinical application of antibody drug conjugates (ADCs), novel cleavage strategies that provide improved selectivity are still needed. Herein is reported the first approach that uses near-IR light to cleave a small molecule from a biomacromolecule, and its application to the problem of ADC linkage. The preparation of cyanine antibody conjugates, drug cleavage mediated by 690 nm light, and initial in vitro and in vivo evaluation is described. These studies provide the critical chemical underpinning from which to develop this near-IR light cleavable linker strategy.
Collapse
Affiliation(s)
- Roger R Nani
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD (USA)
| | - Alexander P Gorka
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD (USA)
| | - Tadanobu Nagaya
- Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD (USA)
| | - Hisataka Kobayashi
- Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD (USA)
| | - Martin J Schnermann
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD (USA).
| |
Collapse
|
99
|
Nani RR, Gorka AP, Nagaya T, Kobayashi H, Schnermann MJ. Near-IR Light-Mediated Cleavage of Antibody-Drug Conjugates Using Cyanine Photocages. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201507391] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
100
|
Gébleux R, Wulhfard S, Casi G, Neri D. Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates. Mol Cancer Ther 2015; 14:2606-12. [PMID: 26294742 DOI: 10.1158/1535-7163.mct-15-0480] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Accepted: 08/06/2015] [Indexed: 01/11/2023]
Abstract
The development of antibody-drug conjugates (ADC), a promising class of anticancer agents, has traditionally relied on the use of antibodies capable of selective internalization in tumor cells. We have recently shown that also noninternalizing antibodies, coupled to cytotoxic drugs by means of disulfide linkers that can be cleaved in the tumor extracellular environment, can display a potent therapeutic activity. Here, we have compared the tumor-targeting properties, drug release rates, and therapeutic performance of two ADCs, based on the maytansinoid DM1 thiol drug and on the F8 antibody, directed against the alternatively spliced Extra Domain A (EDA) domain of fibronectin. The antibody was used in IgG or in small immune protein (SIP) format. In both cases, DM1 was coupled to unpaired cysteine residues, resulting in a drug-antibody ratio of 2. In biodistribution studies, SIP(F8)-SS-DM1 accumulated in the tumor and cleared from circulation more rapidly than IgG(F8)-SS-DM1. However, the ADC based on the IgG format exhibited a higher tumor uptake at later time points (e.g., 33%IA/g against 8%IA/g at 24 hours after intravenous administration). In mouse plasma, surprisingly, the ADC products in IgG format were substantially more stable compared with the SIP format (half-lives >48 hours and <3 hours at 37°C, respectively), revealing a novel mechanism for the control of disulfide-based drug release rates. Therapy experiments in immunocompetent mice bearing murine F9 tumors revealed that SIP(F8)-SS-DM1 was more efficacious than IgG(F8)-SS-DM1 when the two products were compared either in an equimolar basis or at equal milligram doses.
Collapse
Affiliation(s)
- Rémy Gébleux
- Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zürich, Zurich, Switzerland
| | | | | | - Dario Neri
- Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zürich, Zurich, Switzerland.
| |
Collapse
|